MILWAUKEE, Jan. 15, 2026 /PRNewswire/ -- Ademi LLP is investigating Penumbra (NYSE: PEN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Boston Scientific. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.  There is no cost or obligation to you. In the transaction, Penumbra stockholders can elect to receive $374 in cash or 3.8721 shares of Boston Sc ...